HbA1c: Reading your three-month glucose average

What HbA1c actually is, biologically speaking

HbA1c measures the proportion of hemoglobin — the oxygen-carrying protein in red blood cells — that has become glycated: chemically bonded to glucose through a non-enzymatic reaction on the beta chain. The higher average blood glucose runs, the more hemoglobin ends up glycated. Because red blood cells circulate for roughly 90–120 days before being replaced, the resulting percentage reflects average glucose exposure over that window, weighted toward the most recent 4–6 weeks. This relationship has been quantified in large studies (the ADAG trials), allowing HbA1c to be translated into an estimated average glucose — so a 5.7% result maps to roughly the low 100s mg/dL — providing a practical bridge between the percentage and a familiar glucose unit.

The three-month glycemic memory behind HbA1c

The glycation process works like slow browning: glucose forms stable chemical links with hemoglobin over time, accumulating a record of how often and how high glucose has run. Spikes after high-carbohydrate meals, elevated fasting glucose from poor sleep or chronic stress, and sustained post-meal elevations all contribute to the running average that HbA1c captures. What it does not capture is day-to-day glucose variability or post-meal spikes in isolation — a normal HbA1c can coexist with frequent post-meal peaks if fasting glucose is consistently low enough to pull the average down.

HbA1c also assumes red blood cells live their typical lifespan. Conditions that shorten RBC survival — hemolytic anemia, iron deficiency anemia, thalassemia, and chronic kidney disease — cause HbA1c to read falsely low, because newer cells have had less time to accumulate glycation. Conversely, anything that extends RBC lifespan can push the reading artificially high, independent of true glucose exposure. These confounders mean the number must always be read alongside clinical context.

Large trials demonstrate that lowering HbA1c reduces microvascular complications — diabetic eye, kidney, and nerve disease — and that cardiovascular risk trends upward as HbA1c drifts from the mid-5s into the 6s, even before a formal diabetes diagnosis. At the same time, the ACCORD trial found that ultra-aggressive lowering raised risk in certain high-risk groups, a reminder that context and safety matter as much as the number itself.

Reading your HbA1c number with confidence

Widely used diagnostic thresholds, established by the ADA and international guidelines, place results below 5.7% in the normoglycemic range, 5.7–6.4% in the increased-risk (prediabetes) range, and 6.5% or above in the diabetes-diagnostic range when confirmed by repeat testing or other criteria. These cutoffs reflect population-level risk data, not universal optima — interpretation shifts with age, pregnancy, anemia, kidney disease, and hemoglobin variants. Labs may report in percent (NGSP/DCCT-aligned) or mmol/mol (IFCC), and the same sample can read slightly differently across platforms, which is why consistent use of the same lab and assay method matters for trend tracking.

When levels run high

Elevated HbA1c generally reflects average glucose running above target for weeks. Contributing factors include insulin resistance, reduced insulin production, high-glycemic eating patterns, sedentary time, sleep loss, and medications that raise glucose — glucocorticoids in particular. Chronic stress and sleep apnea can keep fasting glucose elevated even in the absence of obvious dietary causes. Fasting glucose and an oral glucose challenge can clarify whether elevation is predominantly post-meal or sustained throughout the day; continuous glucose monitoring adds timing and variability data. Elevated triglycerides and HDL patterns can hint at insulin resistance, and liver enzymes such as ALT can point toward fatty liver disease, which often co-occurs with higher HbA1c in metabolic syndrome.

When levels run low

A low HbA1c is not automatically favorable. In people on glucose-lowering therapy, very low values can indicate frequent hypoglycemic episodes. Outside of therapy, low readings may reflect faster red blood cell turnover — hemolytic anemia, recent blood loss, transfusions, or kidney and liver conditions that shorten cell lifespan. Pregnancy alters red cell dynamics and iron status, making HbA1c less reliable after the first trimester; oral glucose tolerance testing, fingerstick monitoring, or CGM are preferred in that context. Certain hemoglobin variants (HbS, HbC) can bias results depending on the assay method, though many modern platforms are designed to minimize this interference. When HbA1c appears out of sync with fingerstick readings or a CGM trace, short-term glycation markers such as fructosamine or glycated albumin — which reflect a 2–3 week window — can provide a more reliable average.

Why HbA1c can mislead: RBC turnover and beyond

The most structurally important influence on HbA1c accuracy is red blood cell lifespan. Iron deficiency anemia causes HbA1c to read artificially high — not because glucose is elevated, but because iron-deficient cells accumulate more glycation per unit time. Correcting iron status can shift the HbA1c reading without any change in actual glucose exposure. Hemolysis and other conditions that accelerate RBC turnover push the reading in the opposite direction, producing a falsely low result.

Beyond RBC dynamics, several physiological and pharmacological factors influence the glucose average that HbA1c does legitimately reflect. Dietary carbohydrate composition matters mechanistically: fiber slows glucose absorption by moderating gastric emptying, producing smaller post-meal rises; protein and fat have similar moderating effects on glucose entry rate. Muscle contraction opens GLUT4 channels independently of insulin, clearing glucose from the bloodstream — a mechanism that explains why physical activity, particularly after meals, attenuates post-meal glucose rises and, with consistent practice, shifts the baseline average downward.

Cortisol and other stress hormones raise fasting and post-meal glucose by promoting hepatic glucose output and reducing peripheral insulin sensitivity. Sleep disruption amplifies this effect through altered cortisol and growth hormone pulsatility; sleep apnea adds intermittent hypoxia, which independently worsens insulin resistance. Glucocorticoid medications replicate the cortisol effect pharmacologically and can substantially elevate HbA1c in people who require them long-term. Proton pump inhibitors and metformin can deplete vitamin B12, and while this does not directly alter HbA1c, secondary effects on red cell morphology are worth noting in the broader interpretive picture. Pregnancy changes both red cell turnover and insulin requirements simultaneously, which is why OGTT, fingerstick monitoring, and CGM are preferred over HbA1c for gestational diabetes diagnosis and management.

The markers that read HbA1c in proper context

• Fasting glucose — the same-day snapshot of baseline glycemia. When fasting glucose is normal but HbA1c is elevated, post-meal spikes are likely driving the average; the two together reveal glucose timing patterns that neither captures alone.
• Fructosamine — the two-to-three-week complement to HbA1c. When HbA1c is unreliable due to hemolysis, iron deficiency, or hemoglobin variants, fructosamine provides the medium-term glycemic average that HbA1c cannot.
• Insulin — fasting insulin reveals whether the pancreas is compensating for resistance. A normal HbA1c alongside elevated fasting insulin can indicate early insulin resistance before the glucose average has risen enough to register.
• ALT — elevated ALT can indicate fatty liver disease, which worsens overnight hepatic glucose output and frequently co-occurs with elevated HbA1c in the metabolic syndrome cluster.
• Triglycerides — high triglycerides alongside elevated HbA1c points toward hepatic insulin resistance; the co-occurrence maps the metabolic syndrome cluster and helps guide next clinical steps.

Why an 8-week HbA1c retest is uninformative

HbA1c reflects the glycation accumulated across the full lifespan of circulating red blood cells — approximately 90–120 days. Retesting in fewer than 8 weeks is uninformative because the red blood cell population has not turned over sufficiently to reflect any genuine change in glucose exposure; the result will still be dominated by cells that were present before any intervention began. A meaningful signal requires at least 8 weeks, and 12 weeks provides a cleaner read.

The ADA recommends quarterly HbA1c testing for people actively managing diabetes, where tracking treatment response matters. For stable individuals without diabetes who are monitoring metabolic health, annual testing is generally appropriate. Whenever possible, retest at the same laboratory using the same assay method — NGSP and IFCC platforms can produce small numerical discrepancies on the same sample, and switching between them mid-trend introduces noise that is not biologically meaningful.

When HbA1c becomes a clinician conversation

HbA1c warrants a direct clinical conversation in several circumstances: a result at or above 6.5% on a single test (or 5.7–6.4% on a trend that is moving upward); a result that is inconsistent with daily glucose readings, CGM data, or symptoms; a low result in the context of glucose-lowering therapy, where hypoglycemia may be occurring silently; or any result in a person with hemolytic anemia, iron deficiency, a known hemoglobin variant, advanced kidney disease, or pregnancy, where the number may not accurately represent true glycemic exposure. In these situations, confirming with a complementary measure — fructosamine, fasting glucose, OGTT, or CGM — before acting on the HbA1c alone is appropriate.

Used as a trend rather than a single data point, HbA1c functions as a quarterly report on how sleep, movement, nutrition, and stress physiology are collectively landing. Early drift upward — from the low 5s toward the mid-5s, or from the mid-5s toward 6% — is the window where course correction is most reversible. Pairing HbA1c with the companion markers above gives the full metabolic picture that a single number cannot provide on its own.

Superpower's approach to metabolic health, outlined in the manifesto, is built around exactly this kind of layered, trend-based interpretation — combining HbA1c with fasting glucose, insulin, lipids, and liver markers so that the data tells a coherent story rather than a single isolated number.